MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock-Follow On...
$93,243K
Proceeds from issuance of
common stock-At The...
$19,012K
Proceeds from employee
stock purchase plan
$467K
Proceeds from exercise of
stock options
$219K
Net cash provided by
financing activities
$112,685K
Canceled cashflow
$256K
Net increase in cash
and cash...
$53,660K
Canceled cashflow
$59,025K
Payments of deferred
offering costs
$256K
Stock-based compensation
$10,038K
Non-cash operating lease
expense
$1,080K
Depreciation and
amortization
$323K
Loss (gain) on sale of
property and equipment
-$67K
Other long-term
assets
-$3K
Sales and maturities
of marketable...
$159,020K
Net cash used in
operating activities
-$55,312K
Net cash used in
investing activities
-$3,713K
Canceled cashflow
$11,511K
Canceled cashflow
$159,020K
Net loss
-$59,978K
Purchases of marketable
securities
$162,502K
Prepaid expenses and
other current assets
$3,396K
Operating lease
liabilities
-$1,261K
Accounts payable
-$869K
Accretion of
premiums/discounts on marketable...
$791K
Accrued expenses
-$516K
Gain on marketable
securities
$12K
Purchase of property and
equipment
$231K
Back
Back
Cash Flow
source: myfinsight.com
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)